Advertisement

Capsule Commentary on Zueger et al., Older Medicare Beneficiaries Frequently Continue Medications with Limited Benefit Following Hospice Admission

  • Rebecca BergerEmail author
Capsule Commentary

Zueger and colleagues1 found that Medicare beneficiaries were often continued on “limited benefit medications” (LBM) after enrollment in hospice.

Why do physicians continue limited benefit medications in hospice patients? Discontinuing medications requires difficult conversations with patients and families about the value of medications relative to a patient’s life expectancy. In this cohort, anti-dementia medications were more likely to be continued than other medications. Families experience difficulty stopping these medications,2 possibly due to their perceived impact on cognition, memory, and personality. Anti-hyperlipidemics were among the least likely to be continued. Their benefit is almost exclusively long-term; in one study, few patients with life-limiting illness had concerns about discontinuing statins.3 While the authors excluded patients who may benefit from LBMs, such as continuation of an anti-hyperlipidemic after recent myocardial infarction or stroke, the list of exclusions was not comprehensive; for some patients it may be appropriate to continue medications that are of limited benefit to the general hospice population.

This study adds to existing literature that suggests that we may overtreat patients at the end of life.4, 5 Avoiding medications which are unlikely to provide symptomatic benefit, which contribute to pill burden and expose the patient to unnecessary side effects, should be a focus of end-of-life care.

Notes

Compliance with Ethical Standards

Conflict of Interest

The author declares that she does not have a conflict of interest.

References

  1. 1.
    Zueger PM, Holmes HM, Calip GS, Qato DM, Pickard S, Lee TA. Older Medicare Beneficiaries Frequently Continue Medications with Limited Benefit Following Hospice Admission. J Gen Intern Meed.  https://doi.org/10.1007/s11606-019-05152-x.
  2. 2.
    Shega JW, Ellner L, Lau DT, Maxwell TL. Cholinesterase Inhibitor and N-Methyl-D-Aspartic Acid Receptor Antagonist Use in Older Adults with End-Stage Dementia: A Survey of Hospice Medical Directors. J Palliat Med. 2009;12(9):779–783.  https://doi.org/10.1089/jpm.2009.0059.CrossRefGoogle Scholar
  3. 3.
    Tjia J, Kutner JS, Ritchie CS, et al. Perceptions of Statin Discontinuation among Patients with Life-Limiting Illness. J Palliat Med. 2017;20(10):1098–1103.  https://doi.org/10.1089/jpm.2016.0489.CrossRefGoogle Scholar
  4. 4.
    Todd A, Husband A, Andrew I, Pearson S-A, Lindsey L, Holmes H. Inappropriate prescribing of preventative medication in patients with life-limiting illness: a systematic review. BMJ Support Palliat Care. 2016;7(2):113–121.  https://doi.org/10.1136/bmjspcare-2015-000941.CrossRefGoogle Scholar
  5. 5.
    Tjia J, Briesacher BA, Peterson D, Liu Q, Andrade SE, Mitchell SL. Use of Medications of Questionable Benefit in Advanced Dementia. JAMA Intern Med. 2014;174(11):1763.  https://doi.org/10.1001/jamainternmed.2014.4103.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine 2019

Authors and Affiliations

  1. 1.Department of MedicineWeill Cornell MedicineNew YorkUSA

Personalised recommendations